GRIFOLS, S.A.
Headquarters address: C/ Jesús y María, 6 Barcelona
CIF A58389123 Spain Health Pharmaceutical IBEX35 seen 1674 times Last report December 2020
Employees | 737 (41.70% women) |
Profit | 618.5M € |
Indebtedness | 127.3% |
Income | 5,340M € |
Earnings per share | 0.9 € |
Solvency | 178.6% | -2.05% |
Short solvency | 87.08% | -26.46% |
Working balance on income | 34.27% | -20.72% |
Working balance on assets | 57.81% | -11.18% |
Non current assets coverage | 42.18% | -5.3% |
Fixed assets on long term debt | 70.76% | -3.51% |
Cash on Current Assets | 18.31% | -25.9% |
Inmovilization | 79.28% | 2.68% |
Cash on Current Liabilities | 43.41% | -38.68% |
Leverage | 46% | 0.77% |
Debt Quality | 84.39% | -1.3% |
Financial Expenses Coverage | 399% | 14.95% |
Short term Indebtedness | 19.87% | 12.75% |
Long term Indebtedness | 107.4% | 3.39% |
Financial Expenses on EBIT | 25.06% | -13.01% |
Indebtedness Ratio | 56.01% | 2.09% |
Indebtedness on EBIT | 858.8% | 0.88% |
Assets Turnover | 34.96% | 1.87% |
Customers Turnover | -1.17K% | 11.98% |
Fixed Assets Turnover | 44.1% | -0.78% |
Suppliers Turnover | 211.3% | -5.91% |
Profit on Income/Sales | 11.58% | 11.41% |
Earnings per share | 0.9 € | 11.11% |
Funds from Operations | 940.1M € | 8.27% |
EBIT Margin | 18.65% | -0.66% |
Operating Margin | 16.45% | 13.5% |
ROA | 4.05% | 13.5% |
ROE | 12.11% | 16.73% |
Profitability | 5.8% | 0.73% |
Economic Profitability | 6.52% | 1.2% |
Rea Estate Profitability | -116.1% | -60.75% |
Expenses/Profit | 155.9% | -1.31% |
EBIT | -399% | 14.95% |
Staff expenses | 2.11M € | -3.39% |
Financial Expenses on Sales | 4.67% | -13.59% |
Cash Flow per share | -236.2K | -150% |
Cash Flow on assets | -1.06% | -151.1% |
Cash Flow on income/sales | -3.04% | -150.1% |
Dividends on Cash Flow | 0% | -100% |
Cash Flow Margin Ratio | 20.79% | 15.44% |
Cash Flow on short-term Liabilities | 12.16% | -146.5% |
Cash Flow on long-term Liabilities | 2.25% | -150.7% |
Cash Flow on Debt | 2.31% | -150.7% |
External Financing | 218.3% | -328.3% |